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Background: Epithelial Ovarian Cancer (EOC) is the second most common gynaecological cancer and accounts for
more deaths than all gynaecological cancers combined. Despite extensive research, progress has been slow in
understanding the pathobiology. EOC is identified as a heterogeneous malignancy with various histological
subtypes. It is now well known that these different histological subtypes show differences in terms of presentation,
response to treatment, immunohistochemical (IHC) reactivity and molecular profiling. Cell cycle deregulation is key
in cancer development and there is some evidence in the literature that this is relevant to the problem of EOC and
the development of drug resistant disease. The need to identify prognostic markers has led to several gene
profiling studies using tumour tissue with equivocal results. p57kip2 is one such cell cycle regulator and its functions
are being explored as recent research has shown that it is more than just a negative regulator of the cell cycle.
Aims: The aim of this review is to evaluate the literature around the IHC expression of p57kip2 in EOC.
Methods: Systematic review of the literature focussing on clinical outcome and immunohistochemical expression
in epithelial ovarian cancer.
Results: Four papers are discussed in this review and have shown great variation in IHC expression of p57kip2 in
EOC. These studies incorporated different histological subtypes of EOC. However they all suggest that p57kip2 has a
significant role in prognosis and its therapeutic indication needs to be studied. Multicentre collaborative studies on
individual histological subtypes might provide more data and help to increase the number of cases especially for
rarer tumours.
Keywords: Epithelial ovarian cancer, Pathobiology, Histology, Immunohistchemistry, Cell cycle, Cyclin dependant
kinase, p57kip2Introduction
In 2008, epithelial ovarian cancer (EOC) accounted for
225,000 new cases worldwide and causes 140,100 deaths
[1]. EOC is the second most common gynaecological
cancer and accounts for more deaths than all gynaeco-
logical cancers combined. In the UK, there were 6,537
new cases of ovarian cancer diagnosed in 2008 and
4,440 women died of ovarian cancer in 2008 [2]. Treat-
ment for EOC includes surgery and chemotherapy.
Although there have been some advances in treatment* Correspondence: docmadhuri231@doctors.org.uk
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reproduction in any medium, provided the orand management of this disease, more than 75% of cases
at presentation are advanced Stage 3/Stage 4 with a very
poor 5 year survival (20-30%) [3].
Despite extensive research, progress has been slow in
understanding the pathobiology of the cause and pro-
gression of EOC. In their landmark paper on the hall-
marks of cancer, Hanahan and Weinberg suggested six
essential cell physiology alterations that led to cancer de-
velopment and followed this with an updated review
considering 2 further enabling characteristics including
genetic instability and tumour promoting inflammation
together with avoiding immune destruction [4,5]. In par-
ticular, and in relation to the present review, the evasion
of growth suppressors and the concomitant drive onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and/or p53 have been the subject of many research studies.
Hanahan and Weinberg included a focus on therapeutic
targeting of the hallmarks of cancer involving cyclin-
dependent kinase inhibitors, which is particularly relevant
to this review [5].
Cell cycle deregulation is key in cancer development
and there is some evidence in the literature that this is
relevant to the problem of EOC and the development of
drug resistant disease [6]. Despite good initial response
to platinum-based chemotherapeutic agents, prognosis
with EOC is poor as there are few effective chemothera-
peutic agents available for management of this disease.
Moreover, there is a need to identify patients who are
likely to relapse whilst undergoing chemotherapy treat-
ment with paclitaxel and carboplatin. The need to iden-
tify prognostic markers has led to several gene profiling
studies using tumour tissue with equivocal results. One
of the criticisms levelled at such studies has been the
possibility for contamination of tumour tissue with stro-
mal components. However, it would seem that less effort
appears to have gone into identification of molecular mar-
kers of prognosis using immunohistochemistry (IHC) of
tissue sections and correlation with clinical outcome. This
approach has the advantage in that the tumour compo-
nent of the tissue can be clearly identified.
EOC is identified as a heterogeneous malignancy with
various histological subtypes. It is now well known that
these different histological subtypes show differences in
terms of presentation, response to treatment, IHC reactiv-
ity and molecular profiling. Molecular studies have demon-























Figure 1 Cell Cycle with various cell cycle regulatory proteins.been posed in previous studies that grouped together all
subtypes when evaluating the expression of the various cell
cycle regulators [7]. Recognition of this has now led
researchers down the path of exploring the individual cell
cycle regulators in various subtypes of cancers. p57kip2 is
one such cell cycle regulator and its functions are being
explored as recent research has shown that it is more than
just a negative regulator of the cell cycle. The aim of this
review is to evaluate the literature around the IHC expres-
sion of p57kip2 in EOC. Firstly, p57kip2 and its role in
tumorigenesis will be discussed with emphasis on EOC
followed by evaluating the reported IHC expression of
p57kip2 in EOC to understand the role of p57kip2 better,
and finally correlating the IHC expression with reported
clinical outcomes.
Cell cycle and p57kip2
The cell cycle is divided into 4 phases: G1, S, G2 and M.
Various cell cycle regulatory proteins act at different
phases in the cycle as shown in Figure 1.
Changes in cell cycle regulation can lead to uncon-
trolled cell proliferation and oncogenesis. The progres-
sion of the cell cycle through the various phases is
tightly regulated by cyclins and cyclin-dependent kinases
(CDKs) and simultaneously counterbalanced by cyclin
dependent kinase inhibitors (CDKIs). The transition
from the G1 to the S phase is regulated by the CDKIs.
The CDKIs are further subdivided into the INK4 family
consisting of p16ink4a, p15ink4b, p18ink4c and p19ink4d and
the CIP/KIP family consisting of p21 waf1, p27 kip1 and
p57kip2. The CIP/KIP family regulates the cell cycle both
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cell cycle phases in keeping with its role as a CDKI. Its
levels also steadily decrease while progressing from G1
through the S cell cycle phase and over expression of
p57kip2 induces G1 arrest in cultured cells.
In humans, the p57kip2 encoding gene (correctly called
the CDKN1C gene) is located on chromosome 11p15.5
and is maternally expressed and paternally imprinted [8].
p57kip2 is distributed in the nucleus, however, cytoplas-
mic distribution has been reported in cancer tissue [8].
It is an important negative regulator and was previously
considered to be a tumour suppressor. Recent findings
of its involvement throughout the regulation of cell cycle
processes suggest a multifaceted existence of the p57kip2
protein [9].
p57kip2 and embryology
p57kip2 has been found to be essential for normal devel-
opment. It is found in derivatives from all the three
germ cell layers and appears to be irreplaceable by other
CDKIs. This has been demonstrated in mouse models
wherein p57kip2 devoid mice die within 2 weeks of age
showing dysregulation in cell proliferation, differenti-
ation and apoptosis as compared to other CIP/KIP fam-
ily proteins which do not appear to be lethal suggesting
that the p57kip2cellular function far exceeds that of its
CDKI counterparts [8]. Rodent data suggests that
p57kip2 is highly cell-specific with a temporal and spatial
p57kip2 expression during embryonic and fetal develop-
ment and continuing on into puberty and adulthood.
The highest and maximum widespread tissue distribu-
tion occurs during organogenesis when p57kip2 is present
in all major organs with its expression peaking at key
differentiation stage for each organ. Levels subsequently
appear to be undetectable in several organs after birth.
Adult human tissue expressing significant p57kip2 mRNA
levels include skeletal muscle, brain, heart, lung, kidney,
pancreas, testis and placenta with lower expression
noted in stomach and ovaries [10].
Altered p57kip2 and cancer
Abnormal p57kip2 function includes its participation in
cancer initiation and progression. Since p57kip2 was dis-
covered as a CDKI, research revolved around describing
its ability to inhibit proliferation hence rendering it a
tumour suppressor gene status [6]. p57kip2 has also been
shown to influence cell differentiation thus positively
inhibiting cancer progression and preventing their main-
tenance in an undifferentiated state. Evading cell death
is a significant ability of cancer cells. Conflicting reports
have been put forth relating to the apoptotic role of
p57kip2. Both pro and anti-apoptotic functions have been
described depending on cellular context, regulatory
tumour cell pathways and tumour microenvironment.However, this evidence is from mouse models with
structural differences compared to humans. Clinical stud-
ies suggest that absence of p57kip2 abrogates the pro-
apoptotic function of anti-cancer therapy resulting in poor
prognosis due to drug resistance development. Vlachos
et al. demonstrated sensitization of cancer cells to apop-
totic agents such as cisplatin, etoposide and other agents
by selective p57kip2 expression [11].
Cancer metastasis is the ability of the cells to travel
and invade neighbouring tissues. This involves regula-
tion of cytoskeletal dynamics, particularly through the
Rho family and a negative feedback loop has been identi-
fied [12]. Nan et al. showed that decreased p57kip2 ex-
pression was associated with increased invasive and
metastatic tumour potential in hepatocelluar carcinoma
[13]. Angiogenesis is another adaptive process of solid
tumours to supply themselves with nutrients and oxygen
for their further growth. Matsuura et al. demonstrated
increased VEGF (vascular endothelial growth factor) ex-
pression in placentae of p57kip2 null embryo mice suggest-
ing a reciprocal correlation between lack of p57kip2 and
VEGF expression though further evidence is awaited [14].
Epigenetic control is important in p57kip2 regulation
frequently via promoter methylation of CpG islands [6].
Transcriptional and translational down-regulation of
p57kip2 has been demonstrated by Pateras et al. in vari-
ous cancers with decreased expression associated with
aggressiveness [10]. Histone modifications of p57kip2 re-
pression helps participate in tumorigenesis in methyla-
tion dependent and in an independent manner. Several
studies have shown that p57kip2 gene reactivation after
demethylating agent treatment in many cancers demon-
strates the epigenetic mechanism of downregulation
[6,10].
p57kip2 and pathology
p57kip2 has been extensively studied in Beckwith-
Wiedemann Syndrome (BWS) which is a heterogenous
disease. Clinical manifestations of pre-eclampsia have
been displayed by mutant mice defective for the mater-
nal p57kip2 allele. Absence of p57kip2 in complete hydati-
diform moles which is a trophoblastic proliferation
abnormality suggests that p57kip2 is a very sensitive mar-
ker to differentiate between complete and partial hydati-
diform mole since p57kip2 is a paternally imprinted and
maternally expressed gene, it is found in partial moles
but absent in complete molar pregnancies [15].
The role of p57kip2 has been studied to a small extent
in cardiovascular and renal pathology as well. Several
IHC studies have been carried out evaluating p57kip2 ex-
pression in lung, oral, gastrointestinal tract (oesophageal,
gastric, colorectal), hepatocellular and pancreatic malig-
nancies [10]. Despite studies highlighting the importance
of p57kip2 in the female genital tract pathology, few
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tic molecular marker for EOC as compared to studies
reported on p27kip1 and p16 [16].
Data currently available are limited and conflicting and
the role of p57kip2 as an IHC marker of prognosis
requires clarification.
Based on the above considerations, we conducted a sys-
tematic review with following meta-analysis to clarify the
association. In this meta-analysis, we examine studies with
IHC data following p57kip2 use. Furthermore, any cor-
relation with clinical outcome is also evaluated to as-




Thorough literature search of MEDLINE, EMBASE, and
COCHRANE electronic databases was performed by 2
independent reviewers to identify relevant studies. This
included bibliographies to identify all additional studies.
Hand searching of the grey literature was also carried
out to identify any relevant conference abstracts and un-
published MD/PhD theses. The search was not limited
to any time duration. To enable assimilation of all rele-
vant published research, all search terms were expanded
and all sub-categories were included. The exact syntax
of search terms included ovarian carcinomas as well as
cell membrane protein and other mesh terms.
Initial scanning of the title and abstract was performed
to exclude any unrelated studies. Reading of the full text
of all remaining articles was performed to determine the
extent of information contained in them on the subject
of interest.
Selection criteria
Inclusion into the current review was based on the fol-
lowing criteria for all retrieved studies:
Tumour site of study performed was ovary. Papers
were reviewed to determine whether IHC assessment of
p57kip2 had been performed. The studies reported the
results of the IHC scoring and an attempt had been
made to correlate this with clinical outcomes. Due to
the small number of studies, reviews that explained the
role of p57kip2 in EOC have also been included following
agreement between the authors.
Studies that did not involve EOC, performed only on
cell lines, western blotting and gene profiling studies
(non IHC studies) have not been reviewed.
Identified studies
Search of the databases using the above search terms led
to identification of a total of 43 papers. All the 43 papers
were independently assessed, 20 of which were excluded
by title alone as not being relevant. 4 papers wererejected following review of the abstracts as p57kip2 was
discussed in relation to molar pregnancy in 3 of these
[16-18]. The 4th paper discussed p57kip2 in relation with
apoptosis and cancer [19]. Extraction onto a datasheet
led to further elimination due to duplication of 2 studies.
Full manuscripts of all the remaining studies were
reviewed. 4 secondary papers were appraised from refer-
ences of the full studies. 14 papers were rejected and a
further 5 review papers have also been rejected for the
purposes of this review. Consequently 4 full papers are
included in the final review as only 4 IHC studies were
identified [20-23]. Results of the search and subsequent
filtering of the studies has been shown in Figure 2.
Data extraction
Information from the studies was extracted by 2
researchers (TKM & BH) using the data extraction form.
Both researchers were in agreement regarding the stud-
ies and the data collected included first author’s name,
country study was performed in, year of publication, no
of cases, IHC findings and clinical outcome if recorded.
Results
The four included studies are tabulated as shown in
Table 1.
The first ever study to evaluate the role of p57kip2
using an IHC approach in EOC was performed by
Rosenberg et al. in 2001 [20]. For comparison purposes,
the cases were divided into 2 groups comparing long
term (>5yrs) vs. short term (<2yrs) survivors. All cases
included had a confirmed diagnosis of ovarian adenocar-
cinomas. Women with FIGO stage 1 and stage 4 were
excluded from this study. Also excluded were women
over the age of 80 at primary diagnosis and cases where
an ECOG performance status of 3 or greater had been
recorded. IHC on 53 cases of treatment naïve (chemo-
therapy/radiotherapy) women following surgery was per-
formed. They included 23 short term and 30 long term
survivors. The histological subtypes of the included cases
are recorded in Table 2.
Immunohistochemical stain assessment was positive
for distinct brown staining and divided into 5 categories;
negative or less than 5% positive, 5% -25% positive, 26%-
50%, 51-75% and greater than 75%. These were then
categorised as low and high immunopositive tumour cell
expressors if less than or greater than 50% respectively.
This study suggested that there was no association
between p57kip2 expression and survival status as com-
pared to the other cell cycle regulators assessed in this
study (Cyclin D1, Cyclin E) Table 3.
The following year, Sui et al. published their results on
p57kip2 expression and its associated clinical relevance in
EOC. 103 cases of ovarian tumours were assessed which
included 33 benign tumours, 23 borderline and 47
Figure 2 Filtering of studies and final number of studies included in the review.
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nosed with Stage 1 disease, 3 Stage 2, 16 and 12 in Stage
3 and 4 respectively. Grading of the 47 tumours revealed
21 G1, 13 each in the G2 and G3 category. All 47 were
treatment naïve. The ratio of positive nuclear staining to
the total number of counted cells was recorded and
immunopositivity was classified as low or high as in the
Rosenberg study with 50% being the cut off. The investi-
gators at this stage were blinded to the clinical outcome.
Highest positivity was recorded in benign tumours and
lowest in the malignancies (Table 4). A statistically sig-
nificant correlation was found between p57kip2 expres-
sion and stage and grade of tumour. Median follow-up
in this study was 24 months (range 2–156) and low
p57kip2 expression was found to be associated with poor
survival suggesting a linkage to a more aggressive pheno-
type of EOC in this category. This study concluded
p57kip2 IHC may confer important prognostic implications
for EOC Table 4.
In 2007, Khouja et al. published their experience with
p57kip2 and other proteins in 171 treatment naïve
patients with Stage 3 EOC (Stage 3a- 13, 3b −20 & StageTable 1 Showing the 4 studies with IHC performed
Author Year Country IHC performed
Rosenberg E 2001 USA Yes
Sui L 2002 Japan Yes
Khouja MH 2007 Norway Yes
Guo J 2011 China Yes3c −138) [22]. Serous adenocarcinoma was the predom-
inant subtype (127/171) and the other subtypes are
shown in Table 2. 156/171 consisted of grade 2/3
tumours and the remaining cases (15/171) were Grade
1. Distinct nuclear staining was considered positive.
Semiquantitative scoring classes were adopted depend-
ing on the number of positive stained tumour cells with
4 scoring groups; no staining, less than 10% positive, be-
tween 10% and 50% positive and more than 50%. The
IHC results for p57kip2 was negative in 19% of the cases
and more than 50% staining was obtained in only 2%
(4 cases). This study concluded that there was no correl-
ation between p57kip2 and clinical and prognostic out-
comes, Table 4.
The final study by Guo et al. in 2011 evaluated 103
ovarian tissues [23]. Of these, 17 were normal ovaries,
15 benign, 8 borderline, 55 EOC and 8 non-epithelial
tumours as shown in Table 2. Positive staining was
defined as brown-yellow granules distributed in either
the nucleus or cytoplasm with higher intensity of stain
than the nonspecific background. Greater than 20%





Table 2 Showing histological subtypes of the 4 studies
Author No of EOC
cases
Histological subtype Scoring





Sui L 47 Not mentioned Low vs high
Expressors21 Grade1
13 Grade 2
13 Grade 3 incl 2
undifferentiated






Mixed without clear cell 4
Mixed with clear cell 4
Unclassifiable adenoca 6












Table 3 Patient Demographics recorded in the studies is tabu
Author No of EOC
cases




Rosenberg E 53 <80 Naïve 2 &
Sui L 47 16-77
Median 49
Naïve 1-4
Khouja MH 171 21-70
Median 54
Naïve 3 on
Guo J 103 18-66
Median 42
Naive 1-4
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zeste homolog 2) and compared p57kip2 IHC expression
since p57kip2 is a direct target of EZH2 as shown in
other studies. No assessment of correlation p57kip2 and
clinical outcome was looked into. The study concluded
that EZH2 depletion increased p57kip2 expression indi-
cating that EZH2 acts as an EOC oncogene by targeting
p57kip2 Table 4.
Discussion
The above 4 studies demonstrated varying results. There
are several factors that might explain the discrepancies
seen in our meta-analysis. The first criterion might in-
volve the technique used – particularly with respect to
the antibody used. While Rosenberg and Sui et al. used
polyclonal p57kip2 antibodies at dilutions of 1:25 and
1:500 respectively, Khouja et al. used a monoclonal p57
kip2 antibody at 1:500 dilutions. Whilst it is common
knowledge that high specificity of monoclonal antibodies
decreases cross-reactivity and background noise provid-
ing reproducible results and might explain the results by
Khouja et al., it is unclear whether technique alone may
explain the differences in the results of Rosenberg and
Sui et al. Other variations in technique depending on
the timing, type of autostaining technology employed
(e.g. Dako/Ventana) may also account for the differ-
ences in results. This may also explain the differences
in the p57kip2 in normal ovarian tissue which was
observed by Sui & Guo et al. and none of the 10 cases
in Khouja et al. series showed the expression. Only Sui
& Guo et al. have assessed for expression in normal
ovarian tissue and along the spectrum of ovarian
tumours ranging from benign to borderline to malig-
nant. While this gives an indication of p57kip2 expres-
sion across the tumour gradient, meaningful data
analysis remains difficult from such small numbers.
Rosenberg et al. included only stage 2 & 3 EOC cases
in their study. Since EOC tends to present as an
advanced stage disease (>Stage 3) in more than 80% of
cases excluding cases of stage 4 disease which represents
a big cohort of the cases is unlikely to shed meaningful
results especially when extensive drug developmentlated below
Stage of Grade (G) Other mentioned criteria
3 only only G3
mentioned
ECOG status
G1 vs G2/3 Nodal status, ascites, residual disease
ly G1 vs G2/3 Ascites, residual disease and response to
chemotheraphy
G1/G2/G3 Nodal status






Rosenberg E 48/53 n/a n/a n/a No relation to survival status
Sui L 19/47 21/33 Normal ovarian tissue
expression was positive
(data not included)
12/23 Significant correlation between p57kip2 expression and tumour
grades/clinical stages noted. Low p57kip2 expression associated
with poor survival. Important prognostic implications exist
Khouja MH <10%Positivity in
130/171 & >10% in
41/171
n/a n/a No correlation exists with clinical and prognostic outcomes
0/10 positivity in normal
Ovarian tissue
Guo J 15/55 12/15 Normal ovarian tissue
expression was positive in
16/17
6/8 Not described as clinical correlation not assessed
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attempt to improve survival. Due to more aggressive
treatment (surgery & chemotherapy) survival in Stage 4
disease has definitely improved from the 13% 2 year
survival mentioned in Rosenberg et al. to around 30-40%
5 year survival.
On the contrary, involving the early stages may shed
light on the tumour development and biology which
might improve our understanding of this silent killer dis-
ease and possibly assist in moving a step closer towards
the ultimate dream of an ovarian cancer vaccine.
All 4 studies have clarified the grade of tumours as
shown in Table 4. 3 out of the 4 studies focused on the
adenocarcinomas and clearly describe the number of
cases in each histological subtype though one wonders
whether focusing on one subtype or histological sub-
type might yield clarity of data especially in studies with
small number of cases.
Future work
The above studies interestingly have shown great variation
in IHC expression of p57kip2 in EOC. This has obviously
then led to differing conclusions being drawn as to the use-
fulness of this cell cycle regulator as an IHC marker for
EOC. Conflicting results from the above studies may be
explained by differences in technique, type of antibodies,
case selection and different methodologies as described
above. However, while the above studies incorporated the
different histological subtypes of EOC, work on individual
histological subtypes might provide more data. Multicentre
collaborative studies might help to increase the number of
cases especially for rarer tumours (e.g. clear cell). Com-
bined IHC coupled with serum and RNA work to assess
the full range of p57kip2 expressed in a wide variety of ovar-
ian cancers along with a complete clinical dataset might
help clarify the discrepancy from the above studies.
p57kip2 as potential prognostic and therapeutic marker
Originally discovered as a CDKI, and considered as hav-
ing only tumour suppressor function, it is becomingobvious that the role of p57kip2 has expanded beyond
cell regulation. The above studies show that low p57kip2
function is associated with high grade, advanced clinical
stage and overall poor prognosis [23]. This association
may become crucial in target oriented cancer therapy by
modulating p57kip2 levels. Several clinical trials including
some Phase I & II clinical trials in haematological malig-
nancies and some solid tumours are currently looking at
reactivation of p57kip2 in cancer cells as a therapeutic
strategy. This is based on the principle that downregula-
tion of p57kip2 in the majority of cancers makes it an ob-
vious tumour suppressor candidate [24]. As shown in
various studies, suppression of the protein expression is
due to the loss of p57kip2activity in cancer. Reactivation
of p57kip2 expression can be a useful mechanism and
some therapies (HDAC inhibitors and demethylating
agents) that cause reactivation are already being used
successfully.
Conclusion
The involvement of p57kip2 is certainly more than just
inhibition of cell growth as was previously thought. It is
now known that its function includes promotion of cell
differentiation and apoptosis and metastasis inhibition.
In trying to unravel the mystery of p57kip2, its role as a
diagnostic marker in the differential diagnosis of early
hydatidiform mole has emerged. The four studies
discussed above have suggested a role for p57kip2 as a
prognostic marker at various levels and needs further
clarification. With aggressive surgery being advocated
for EOC including secondary debulking surgery, serial
IHC work in conjunction with cell line and serum work
from women at varying stages of treatment for EOC
(both chemo-naïve and post treatment) may help to elu-
cidate its role better. It may also help clarify its role in
the development of drug resistance in women following
first line platinum chemotherapy, both to assess poten-
tial response to treatment and to further explore if upre-
gulation helps prevent development of resistance. Larger
number of cases from each individual histological
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emerge which might require collaborations. As a protein
that appears to regulate various functions in the “cancer
hallmarks cycle” resolving the enigma of its function
might provide interesting results in terms of prognosis
and therapy for EOC.
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